You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Prevalence of resistant HIV-1 strains

From: Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs

Mutationa Prevalence Infectious status  
  Totalb in combinationc Long-standing Infection Recent Infection  
  All patients Subtype B N (%) > 6 months (N = 197) ≤ 6 months (N = 58) P-value d
  N (%/255) N (%/213)     
Major Drug resistance mutations
Any 15 (5.9) 15 (7.0) 9 (60.0) 13 (6.6) 2 (3.4) 0.09
NRTI       
Any 10 (3.9) 10 (4.7) 8 (80.0) 8 (4.1) 2 (3.4) 1
Any TAM 7 (2.6) 7 (3.3) 7 (100) 6 (3.0) 1 (1.7) 1
Any TAM1 7 (2.6) 7 (3.3) 7 (100) 6 (3.0) 1 (1.7) 1
Any TAM2 1 (0.4) 1 (0.5) 1 (100) 0 (0.0) 1 (1.7) 0.2
M41L 4 (1.6) 4 (1.9) 4 (100) 3 (1.5) 1 (1.7) 1
D67N 1 (0.4) 1 (0.5) 1 (100) 0 (0.0) 1 (1.7) 0.2
T69D 1 (0.4) 1 (0.5) 0 (0.0) 0 (0.0) 1 (1.7) 0.2
M184V 1 (0.4) 1 (0.5) 1 (100) 1 (0.5) 0 (0.0) 1
L210W 6 (2.3) 6 (2.8) 6 (100) 5 (2.5) 1 (1.7) 1
T215Y 2 (0.8) 2 (0.9) 2 (100) 1 (0.5) 1 (1.7) 0.4
T215D/S 8 (3.1) 8 (3.8) 6 (75.0) 8 (4.1) 0 (0.0) 0.2
NNRTI       
Any 9 (3.5) 9 (4.2) 5 (55.5) 8 (4.1) 1 (1.7) 0.7
L100I 2 (0.8) 2 (0.9) 2 (100) 2 (1.0) 0 (0.0) 1
K101E 2 (0.8) 2 (0.9) 0 (0.0) 2 (1.0) 0 (0.0) 1
K103N 7 (2.7) 7 (3.3) 5 (71.4) 6 (3.0) 1 (1.7) 1
P225H 1 (0.4) 1 (0.5) 1 (100) 1 (0.5) 0 (0.0) 1
PI       
Any 1 (0.4) 1 (0.5) 1 (100) 1 (0.5) 0 (0.0) 1
L90M 1 (0.4) 1 (0.5) 1 (100) 1 (0.5) 0 (0.0) 1
Polimorphism at major resistance related positions
NNRTI       
Any 8 (3.1) 8 (3.8) 1 (12.5) 7 (3.6) 1 (1.7) 0.69
K101Q/R 6 (2.3) 6 (2.8) 1 (16.7) 5 (2.5) 1 (1.7) 1
K103Q/R 3 (1.2) 3 (1.4) 1 (33.3) 3 (1.5) 0 (0.0) 1
  1. a Mutations that have been associated with transmitted drug resistance (Shafer et al., 2007) are reported.
  2. b Number (%) of drug resistance mutations.
  3. c Number (%) of drug resistance mutations that occurs in combination with other major mutations in a sequence. The percentages were calculated in patients containing each specific mutation.
  4. d Data were analyzed by using Fisher exact test.
  5. Abbreviations: PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; TAMs, thymidine analogue associated mutations